Dr. Richter describes why personalized medicine is the future of myeloma treatment.

Join Dr. Richter as he explains the biggest study from EHA and ASCO 2022 and what it means for patients who are transplant eligible.

In this activity, Dr. Richter describes what the current challenges are when managing patients with multiple myeloma.

Join Dr. Usmani as he describes how clinicians should monitor patients after their first or second dose after switching from IV daratumumab to subcutaneous.

Dr. Lonial discusses the impact of safety and efficacy in four-drug regimens compared to the three-drug regimens for frontline therapy.

In this activity, Dr. Baljevic discusses the side-effect profile associated with four-drug regimens.

In this activity, Dr. Baljevic explains the NCCN guidelines outlining four-drug combinations listed for use in newly diagnosed transplant-eligible patients.

In this activity, Dr. Raje provides a summary of the KarMMa trial and BB2121 in relapsed/refractory multiple myeloma.

Dr. Raje explains therapeutic interventions for smoldering multiple myeloma, as well as how to better risk-stratify patients.

In this activity, Dr. Noopur Raje discusses how to risk-stratify patients with smoldering myeloma and the updated definition of symptomatic myeloma.